ADVERTISEMENTs
Chandra Mohan to lead UH Cancer Biomarker project
The grant will be utilized to advance cancer immunotherapy research through cutting-edge proteomic technologies.
-
Bhavana P - Mon, 07, Jul 2025
- 14:48 EDT
- 71
Chandra Mohan / University of Houston
Chandra Mohan, an Indian-American biomedical researcher, has been appointed as the project director of the University of Houston (UH)'s Cancer Immunotherapy Biomarker Core (CIBC), which has been awarded a $3 million grant.
A renowned biomedical engineer and the Hugh Roy and Lillie Cranz Cullen endowed professor, Mohan will lead this initiative from within university’s Drug Discovery Institute.
Also read: Winship Cancer Institute names Neil Iyengar director of survivorship
The facility will be the first in Texas to offer highly advanced targeted proteomics—technology that enables the simultaneous screening of thousands of proteins, significantly accelerating biomarker discovery and treatment development. The funding is part of a larger $93 million grant package from the Cancer Prevention and Research Institute of Texas (CPRIT), a nationally recognized body for cancer research funding.
“Identifying better biomarkers for cancer will accelerate early diagnosis and better prognostication of cancer, better monitoring of disease progression and treatment response possibly leading to the identification of better medications for treating cancer,” said Mohan.
Weiyi Peng, associate professor of biology and biochemistry, will co-lead the project. A specialist in immunoassays and T cell anti-tumor pathways, Peng directs the Drug Discovery Institute’s Immunology Core and brings deep expertise in preclinical model development.
“We are thrilled that Drs. Mohan and Peng received this award. The core is dedicated to immunology research, which aligns with our research priorities,” said Claudia Neuhauser, University of Houston vice president for research.
Rather than attacking cancer cells directly, immunotherapy strengthens the body’s immune system to identify and destroy tumors. The new CIBC facility will support this evolving field by offering four powerful research platforms, including an 11,000-plex targeted proteomic screen and a 21,000-plex protein array—tools that provide unprecedented insight into the human proteome.
Related
.jpg)
.png)
.jpg)
.jpg)
.jpg)
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login